Stay updated on LITT with Checkpoint Inhibitor for RGBM Clinical Trial
Sign up to get notified when there's something new on the LITT with Checkpoint Inhibitor for RGBM Clinical Trial page.

Latest updates to the LITT with Checkpoint Inhibitor for RGBM Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe recurrent glioblastoma study record is now displayed, describing a completed Phase I/II trial of laser interstitial thermotherapy combined with pembrolizumab. It also provides the study design, participant criteria, locations, and outcome measures.SummaryDifference63%

- Check20 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide NIH banner announces a transition in terminology from “artificial intelligence” to “Super Intelligence.” The study page itself remains a 403 error page.SummaryDifference1%

- Check34 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1, while the page continues to display a 403 error.SummaryDifference0.2%

- Check62 days agoChange DetectedAccess to the study record page now renders a 403 Forbidden error, replacing the previous detailed content with an error screen. The change indicates the record is blocked or unavailable rather than updated study data.SummaryDifference21%

Stay in the know with updates to LITT with Checkpoint Inhibitor for RGBM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LITT with Checkpoint Inhibitor for RGBM Clinical Trial page.